Biconvex scored tablets 0.15 g; flat cylindrical scored and beveled tablets 0.45 g and 0.9 g.

Composition

1 g of the product contains active substances:

• Phenibut — 166.7 mg;
• Dry motherwort extract — 33.3 mg.

Excipients: MCC, powdered sugar, colloidal silicon dioxide, calcium stearate.

Pharmacological Properties

ATC vet classification code QN06BX — Other psychostimulants and nootropics. QN06BX22 — Phenibut.

Phenibut, a component of the product, is a phenyl derivative of GABA (gamma-aminobutyric acid) and phenylethylamine. GABA is the main inhibitory neurotransmitter in the central nervous system. It has a positive effect on metabolic processes in brain nerve cells.

Phenibut exhibits nootropic activity and, as a GABA derivative, provides anxiolytic (tranquilizing) effects. It does not affect cholino- or adrenoreceptors. By enhancing inhibitory GABA-ergic processes, it improves functional status through normalization of metabolism and enhancement of cerebral circulation.

It has a pronounced stress-correcting effect and helps normalize excitation and inhibition processes in the central nervous system.

Studies have shown that IZICHELS may reduce anxiety and produce a mild sedative effect. At lower doses, it has a gentle physical and cognitive stimulating effect; at regular or higher doses, it exerts sedative action and promotes deep, restful sleep.

No respiratory depression has been observed with use.

Phenibut is rapidly absorbed after oral administration and penetrates well into all tissues, including crossing the blood-brain barrier.

80–95% of phenibut is metabolized in the liver to inactive metabolites. 5% is excreted unchanged by the kidneys.

Dry motherwort extract: the biologically active substances of motherwort have marked sedative, antispasmodic, hypotensive, and cardiotonic properties; they slow heart rate, increase the strength of contractions, and reduce myocardial oxygen demand.

The combination of phenibut and dry motherwort extract in one product enhances their effects without causing side effects.

Indications

IZICHELS veterinary product normalizes excitation and inhibition processes in the central nervous system, helps stabilize blood pressure, and has a cardiotonic effect for treating behavioral disorders in dogs and cats, particularly aggressive behavior.

IZICHELS is prescribed:

• to reduce arousal and correct psychogenic behavioral disorders in cats and dogs under stress (relocation, injury, grooming, diet change, owner change, loud noises, staying in clinics, shelters), phobias, or unexplained aggression;
• to prevent motion sickness.

Dosage

IZICHELS is administered to cats and dogs orally to the base of the tongue 2 times a day, 15–30 minutes after feeding, according to body weight, in the following doses:

• cats: 5 mg of phenibut and 1 mg of motherwort extract per 1 kg of body weight;
• dogs: 10 mg of phenibut and 2 mg of motherwort extract per 1 kg of body weight.

Doses may be adjusted according to the actual body weight of the animal.

The treatment course is 10–15 days. If signs of severe arousal or behavioral disorders (aggression, fear, hyperactivity, excessive vocalization) persist, the course may be extended to 20 days. If behavioral abnormalities are associated with central nervous system disorders, the course may be extended to 60 days. A 10–15 day course provides effects lasting under 1 month; a prolonged course (up to 60 days) provides effects lasting over 1 month.

If signs of arousal or behavioral disorders reappear, repeat the treatment with the same dosage and schedule.

To prevent stress (transportation, environmental changes, owner's departure, participation in exhibitions or competitions), start administration 5–7 days before the event and continue 3–5 days after its completion.

To prevent motion sickness, administer once in the above doses 1–2 hours before transportation. If signs of motion sickness (vomiting) are already present, the product is less effective.

Contraindications

Individual hypersensitivity to the components (including in anamnesis), acute and chronic renal failure, diabetes, hypertrophic cardiomyopathy.

Do not use in pregnant and lactating females, except in cases of preeclampsia and eclampsia.

Overdose

No data on overdose. At doses 7–10 times the average therapeutic dose, IZICHELS may become hepatotoxic.

Symptoms of overdose: drowsiness, nausea, vomiting, dizziness.

Warnings

Adverse reactions

When used as instructed, no adverse reactions were recorded.

Rarely, after the first dose, animals may experience drowsiness or nausea that resolve without treatment.

In animals with hypersensitivity to the product’s components, excitation, drowsiness, irritability, nausea, or allergic reactions may occur. In such cases, symptomatic and desensitizing therapy should be applied.

Rarely, gastrointestinal discomfort and diarrhea with lower intestinal bleeding may occur in sensitive animals.

Interactions with other agents

Do not use IZICHELS concurrently with CNS depressants, ethanol, benzodiazepines, or opioids. IZICHELS induces cross-tolerance with all GABA-acting depressants, which may reduce their effectiveness.

Special precautions for personnel

Personnel working with the product must follow standard hygiene and safety measures applicable to veterinary products.

Form of Release

IZICHELS for cats (0.15 g tablets): 20 tablets in a blister, 1 blister per box.

IZICHELS for medium-sized dogs (0.45 g tablets): 20 tablets in a blister, 1 blister per box.

IZICHELS for large dogs (0.9 g tablets): 12 tablets in a blister, 2 blisters per box.

Storage

Store in a dry, dark place out of reach of children, at a temperature between 5°C and 25°C.

Shelf Life

3 years.

For veterinary use only!